Top Page
Zura Bio
(NASDAQ:ZURA)
Zura Bio (ZURA) vs. SPDR S&P 500 ETF (SPY)
Zura Bio Business Overview & Revenue Model
Zura Bio Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -75.25M | -55.18M | -62.64M | -27.16M | 8.42M |
| Net Income | -99.35M | -52.40M | -60.36M | -25.74M | 8.42M |
Balance Sheet | |||||
| Total Assets | 113.95M | 179.53M | 100.84M | 5.26M | 140.55M |
| Cash, Cash Equivalents and Short-Term Investments | 109.41M | 176.50M | 99.81M | 1.57M | 729.22K |
| Total Debt | 0.00 | 0.00 | 0.00 | 7.76M | 0.00 |
| Total Liabilities | 12.41M | 19.51M | 21.29M | 27.32M | 10.35M |
| Stockholders Equity | 101.54M | 146.81M | 59.33M | -32.06M | 130.20M |
Cash Flow | |||||
| Free Cash Flow | -64.93M | -28.15M | -23.05M | -13.20M | -1.10M |
| Operating Cash Flow | -64.81M | -28.08M | -15.05M | -1.20M | -1.10M |
| Investing Cash Flow | -113.00K | -5.08M | -8.00M | -12.00M | -139.38M |
| Financing Cash Flow | -2.16M | 109.84M | 121.29M | 14.77M | 141.21M |
Zura Bio Technical Analysis
Zura Bio Risk Analysis
Zura Bio Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $312.89M | 9.56 | 27.78% | ― | -12.96% | 56.02% | |
54 Neutral | $248.42M | 121.36 | -31.79% | ― | 158.54% | 66.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $527.69M | -4.97 | -48.17% | ― | ― | -19.69% | |
50 Neutral | $546.82M | -0.10 | 274.58% | ― | ― | -1072.48% | |
46 Neutral | $167.52M | -5.01 | -99.45% | ― | -11.99% | -42.04% |
Zura Bio Corporate Events
On March 19, 2026, Zura Bio reported its full-year 2025 results, highlighting progress in two ongoing Phase 2 trials of tibulizumab in hidradenitis suppurativa and systemic sclerosis, with HS topline data expected in late 2026 and SSc data in the first half of 2027. During 2025, the company increased R&D spending to $42.1 million, widened its net loss to $68.7 million, and ended the year with $109.4 million in cash and cash equivalents, while a $144 million public offering completed in February 2026, combined with its year-end cash, is expected to fund operations through at least the end of 2028, underpinned by new leadership appointments including CEO Sandeep Kulkarni and two new board members.
Zura also expanded enrollment in its Phase 2 TibuSHIELD trial in hidradenitis suppurativa to 225 participants to enhance statistical power, reinforcing its commitment to the tibulizumab program as the main value driver. The company’s balance sheet strengthening, alongside rising operating expenses and growing accumulated deficit, underscores an intensifying investment phase that could be pivotal for its positioning in the competitive autoimmune and inflammatory disease space, should upcoming clinical readouts support its differentiated mechanism of action.
The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
On March 10, 2026, Zura Bio Ltd., a clinical-stage biotechnology company developing therapies for complex immune disorders, released an updated corporate presentation highlighting its lead asset tibulizumab, a first-in-class bispecific antibody inhibiting both IL-17 and BAFF. The drug, engineered from components of tabalumab and ixekizumab, has shown potent target engagement and low immunogenicity in completed Phase 1 studies, and is being advanced initially in hidradenitis suppurativa and systemic sclerosis, where management sees potential for best-in-class efficacy and first-in-disease treatment across skin and lung manifestations.
The presentation underscores Zura Bio’s strengthened financial position, noting $109 million in cash at year-end 2025 and $144 million in gross proceeds from a February 26, 2026 public offering, which together are expected to fund operations through at least the end of 2028. Topline Phase 2 data readouts for hidradenitis suppurativa and systemic sclerosis are planned for the fourth quarter of 2026 and the first half of 2027, respectively, setting key near-term value inflection points for shareholders as the company seeks to solidify its position in the competitive autoimmune therapeutics space, with about 124 million shares outstanding on an as-converted basis as of March 3, 2026.
The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
On March 5, 2026, Zura Bio announced that the design of its ongoing global Phase 2 TibuSURE trial of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis was accepted for poster presentation at the 9th Systemic Sclerosis World Congress in Athens, Greece, running March 5–7, 2026. The poster will detail the rationale and structure of the randomized, double-blind, placebo-controlled study but will not include clinical efficacy or safety data.
TibuSURE is the first clinical trial to test dual inhibition of IL-17A and BAFF in diffuse cutaneous systemic sclerosis, using tibulizumab, a bispecific antibody designed to target complementary inflammatory and fibrotic pathways in this rare, progressive autoimmune disease with limited treatment options. The study plans to enroll about 80 adults, dosing every four weeks over 24 weeks with an open-label extension and a primary endpoint based on skin score improvement, with topline results expected in the first half of 2027, underscoring Zura’s strategy to establish a differentiated position in systemic sclerosis and broader autoimmune markets.
The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
On February 24, 2026, Zura Bio entered into an underwriting agreement to sell 18.2 million Class A ordinary shares and 1.8 million pre-funded warrants at a public price of $6.25 per share, with the warrants priced at $6.249. The offer was conducted off an effective shelf registration and all securities were sold by the company, with holders of pre-funded warrants subject to ownership caps that limit beneficial ownership to under 10%, adjustable up to 19.99% with advance notice.
The underwriters exercised in full a 30-day option on February 25, 2026 to purchase an additional 3 million shares, bringing expected net proceeds to about $134.6 million after fees, with closing anticipated on February 26, 2026 subject to customary conditions. The transaction materially bolsters Zura Bio’s capital base as it advances its multi-asset immunology pipeline, potentially strengthening its financial position and flexibility in an increasingly competitive autoimmune and inflammatory disease drug-development landscape.
The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
On February 21, 2026, Zura Bio reshaped its board, with longtime director Neil Graham resigning and seasoned immunology and drug development executives Mark Eisner and Ajay Nirula joining as new directors. The appointments, confirmed in a February 23, 2026 announcement, come with standard cash retainers and equity incentives and are expected to strengthen clinical and regulatory oversight as Zura advances its mid-stage programs and positions its pipeline for broader autoimmune and inflammatory disease opportunities.
Eisner, currently Chief Medical Officer at Vir Biotechnology and a former senior leader at Genentech, Sonoma Biotherapeutics, and FibroGen, brings extensive late-stage development and global regulatory experience to the board. Nirula, now Head of R&D at Recludix Pharma and formerly Eli Lilly’s Immunology Therapeutic Area Head, adds deep expertise in immunology drug discovery and development, including prior leadership over tibulizumab’s development before its licensing to Zura, underscoring strategic continuity around the company’s lead asset.
The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
On Feb. 11, 2026, Zura Bio released an updated corporate presentation outlining its strategy to advance tibulizumab, a bispecific antibody designed to inhibit both IL-17 and BAFF, as a novel treatment for complex autoimmune diseases. The company highlighted Phase 1 data showing potent target engagement and low immunogenicity, and positioned tibulizumab as a candidate to overcome efficacy limits seen with single-pathway drugs.
The presentation detailed an initial clinical focus on hidradenitis suppurativa and systemic sclerosis, targeting both skin and lung manifestations in the latter, and framed tibulizumab as a potential best-in-class or first-in-disease therapy in these indications. Management also emphasized Zura Bio’s funding runway through 2027, with topline data from Phase 2 studies in hidradenitis suppurativa and systemic sclerosis expected in the fourth quarter of 2026 and the first half of 2027, milestones that could materially influence its clinical and commercial trajectory.
The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
On January 12, 2026, Zura Bio Limited released an updated corporate presentation and a press release detailing corporate and clinical trial developments, including its outlook for 2026. The company highlighted ongoing Phase 2 studies of its lead dual-pathway antibody tibulizumab in hidradenitis suppurativa and systemic sclerosis, noted expected topline data readouts in late 2026 and the first half of 2027, and emphasized that its current cash position of $139 million as of September 30, 2025 is expected to support operations through 2027, underscoring its funding runway through key clinical milestones.
The most recent analyst rating on (ZURA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
On December 29, 2025, Zura Bio Limited entered into a new Letter Agreement with Athanor Capital and, on the same date, executed settlement and release agreements with Stone Peach and BAFFX17, terminating all outstanding agreements with those parties and securing broad releases of claims in favor of Zura Bio, its subsidiaries and affiliates. Following an internal review conducted by an independent Audit Subcommittee, which was formed and reported on in 2025, the board determined that replacing the Stone Peach arrangements with the Athanor Agreement was more commercially advantageous for the company and its shareholders, and that voiding or terminating the Stone Peach and BAFFX17 agreements would cleanly reset those relationships without financial restatements or findings of employee misconduct; the company now plans incremental enhancements to its internal controls and disclosure procedures that are not expected to materially alter its existing control framework.
The most recent analyst rating on (ZURA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.